Reuters: Actavis has approached Allergan about a deal; Bayer completes Dihon pickup;

Allergan HQ

@FiercePharma: Tops this weekend: Express Scripts ready to favor AbbVie hep C prospect--provided it undercuts. Article | Follow @FiercePharma

@EricPFierce: The revamp continues at Takeda, as does its financial struggles. Article | Follow @EricPFierce

@CarlyHFierce: ICYMI: Express Scripts ready to favor AbbVie hep C prospect--provided it undercuts Gilead. Story | Follow @CarlyHFierce

Survey

Veeva 2020 Unified Clinical Operations Survey

We believe you have the knowledge and expertise to make this year's Veeva 2020 Clinical Operations Report even more robust and insightful than the last. Please take a moment to share your opinion in this 10-minute survey. All qualified respondents will be entered to win a $500 Amazon gift card.

> Allergan ($AGN) says it's been approached about a deal by a company other than pursuer Valeant ($VRX), and Reuters' sources say that company is Actavis ($ACT). Report

> Bayer has completed its pickup of China's Dihon Pharmaceutical Group, an OTC company it agreed to acquire in February. Report

> Planning officials are recommending approval of a scheme for GlaxoSmithKline's ($GSK) £25 million investment in in its Montrose, U.K., API plant. Report

> Pfizer ($PFE) EVP Anthony Maddaluna last week unloaded 2,425 shares of the company's stock. Report

Medical Device News

@FierceMedDev: ICYMI: Diagnostic companies homing on on rapid mobile tests to quell Ebola outbreak. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: ICYMI: UPDATED: Medtronic discloses new corporate structure upon Covidien deal close. Story | Follow @VarunSaxena2

@EmilyWFierce: Boston Scientific set to face first federal trials over transvaginal mesh products. Reuters article | Follow @EmilyWFierce

> With new fund, Rock Health to invest more money in fewer companies. Story

> Boston Scientific faces first two federal trials for transvaginal mesh devices. Article

Biotech News

@FierceBiotech: Nymox blasted as lead drug flops in twin PhIII enlarged prostate studies. News | Follow @FierceBiotech

@JohnCFierce: Bristol-Myers beefs up fibrosis pipeline with $444M option deal. Report | Follow @JohnCFierce

@DamianFierce: $BMY gets into IPF with Galecto (and Magnus Persson, its fantastically named chairman) in a deal worth up to $444M. Release | Follow @DamianFierce

@EmilyMFierce: The planet's deadliest infectious diseases, by country. More via Salon | Follow @EmilyMFierce

> Geron shares rocket up after FDA takes the cuffs off its lead drug. Story

> $6B Covance buyout puts LabCorp in the CRO biz. Report

> Takeda drops a $750M schizophrenia drug pact with Intra-Cellular. Item

CRO News

> PRA raises the stakes, eyeing $400M in a blockbuster IPO. More

> CRO Paragon raises $13M to expand its footprint. Story

> LabCorp is buying Covance for $5.6B to cut in on the CRO boom. News

> Timely deals boost Charles River's balance sheet. Story

> Quintiles posts another $1B quarter and dials up its expectations. Report

Biotech IT News

> Venter makes new hires at Synthetic Genomics and Human Longevity. Item

> Cleveland Clinic teams with IBM to use Watson in genomics cancer research. Report

> Report: GSK, J&J, Merck and Sanofi have made mobile app breakthroughs. More

> Novo Nordisk pushes back date of IT IPO decision to 2015. Story

> Boehringer picks IDBS system in consolidation of ELN. Article

Animal Health News

> IDEXX follows positive earnings with acquisition of Animana. Item

> Advaxis sees encouraging results for immuno-oncology treatment in dogs with bone cancer. Report

> Analysts to Heska: Why has strong performance been overlooked? Article

> Jaguar Animal Health trims IPO target number by 26%. More

> Possible threat to strong launch of Merial's anti-flea pill NexGard adds to Sanofi's woes. Story

And Finally... Amid a lack of competition for snakebite drugs that's kept prices around $50,000 per treatment, an alternative now may hit the market as soon as 2018--10 years earlier than planned--thanks to a new licensing deal. Report

Suggested Articles

After early threats, the FDA finished reviewing the company's response to a citation for data manipulation and decided not to take any further action.

China is quickly getting back up to speed with API production but reports freight bottlenecks are slowing deliveries.

Mylan and Pfizer have already postponed the close of their generic merger amid COVID-19 concerns. Now the pair is hoping to speed up EU review.